Fungal status and outlook in allergic bronchopulmonary aspergillosis
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study looks at how the presence of fungus in lung samples relates to the long-term outlook for people with allergic bronchopulmonary aspergillosis (ABPA). It aims to help doctors better understand the disease and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with allergic bronchopulmonary aspergillosis (ABPA) using current guidelines.
- You have had a sputum or lung fluid sample collected during a hospital stay.
- At least one fungus-related test (culture, GM test, or genetic sequencing) has been done on that sample with a clear result (positive or negative).
- Your full medical records, including history, imaging, lab results, treatment, and follow-up information, are available.
- You are willing to take part in follow-up and have signed a consent form (for new participants).
- You have not had antifungal therapy or other treatments that could affect fungus test results in the past month.
- You do not have other lung infections, lung diseases like tuberculosis or cancer, or severe immune problems.
- You have not been on systemic antifungal drugs in the last month and are not in another interventional trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why some people with asthma get a lung infection from mold called aspergillus. It will help doctors better understand the condition and how to treat it.
This study helps doctors predict whether allergic bronchopulmonary aspergillosis (ABPA)—a serious lung condition caused by fungal allergy—will come back after treatment. Researchers will analyze blood samples and immune system markers to identify patients at higher risk of relapse, which could improve how doctors monitor and treat you.
This trial tests a procedure that uses a bronchoscope to clean mucus from the airways and then spray the antifungal drug amphotericin B directly into the lungs. It may help people whose ABPA is active and not improving with standard treatments.
This study tests if biologic drugs are safe and effective for people with allergic bronchopulmonary aspergillosis (ABPA) who also have severe asthma. It may help if you've had an asthma attack in the past year.
This study uses a computer model to see if it can predict when ABPA (a lung condition) might come back. If you have ABPA and are stable after treatment, this could help doctors monitor you better.
This study tests whether benralizumab, a biologic medicine, works well in real-world settings for people with severe asthma caused by an allergic reaction to a common mold called Aspergillus. You may qualify if you have hard-to-control asthma despite strong medications and recent asthma flare-ups.
Hear when a new ABPA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.